Type 2 diabetes mellitus with diabetic neuropathy, unspecified
ICD-10 Code: E11.40 · Body Part: Ankle/Foot
QME Evaluation Process
Neurological examination, EMG/NCS, monofilament testing. Important for apportionment when neuropathy claimed as industrial. Combined endocrine and neurological impairment.
Typical Impairment Rating
10-30% WPI combined endocrine and neurological
AMA Guides Edition
5th Edition
Common Treatments
Related Conditions
Body Part Guide
Ankle/Foot Evaluation Guide
Impairment rating methods, common conditions, and QME evaluation protocols
QME Specialties for Type 2 diabetes mellitus with diabetic neuropathy, unspecified
Find a QME Specialist
Browse QME-certified physicians who evaluate type 2 diabetes mellitus with diabetic neuropathy, unspecified and related ankle/foot conditions in California.
Browse Physical Medicine & Rehabilitation Physicians →Frequently Asked Questions
What is Type 2 diabetes mellitus with diabetic neuropathy, unspecified (E11.40)?
Type 2 diabetes mellitus with diabetic neuropathy, unspecified is an ICD-10 diagnosis code (E11.40) classified under Internal Medicine conditions. It affects the Ankle/Foot and is occasionally seen in California workers' compensation claims. QME physicians evaluate this condition using AMA Guides 5th Edition protocols.
How is E11.40 rated for impairment?
The typical whole person impairment (WPI) range for Type 2 diabetes mellitus with diabetic neuropathy, unspecified is 10-30% WPI combined endocrine and neurological. The exact rating depends on clinical findings, imaging, and the evaluation method (DRE or ROM) chosen by the QME physician per AMA Guides 5th Edition.
What is the QME evaluation process for E11.40?
Neurological examination, EMG/NCS, monofilament testing. Important for apportionment when neuropathy claimed as industrial. Combined endocrine and neurological impairment.
What treatments are common for Type 2 diabetes mellitus with diabetic neuropathy, unspecified?
Common treatments for Type 2 diabetes mellitus with diabetic neuropathy, unspecified include Glucose control, Gabapentin/pregabalin, Duloxetine, Foot care. Treatment appropriateness and outcomes are considered during the QME evaluation when determining permanent and stationary status and apportionment.